New York 2025-2026 Regular Session

New York Assembly Bill A01057

Introduced
1/8/25  

Caption

Authorizes schools to possess and administer FDA approved opioid reversal agents in emergency situations to negate or neutralize, in whole or in part, the pharmacological effects of an opioid in the human body.

Companion Bills

No companion bills found.

Previously Filed As

NY A02114

Authorizes schools to possess and administer FDA approved opioid reversal agents in emergency situations to negate or neutralize, in whole or in part, the pharmacological effects of an opioid in the human body.

NY S06613

Authorizes schools to possess and administer FDA approved opioid reversal agents in emergency situations to negate or neutralize, in whole or in part, the pharmacological effects of an opioid in the human body.

NY S08991

Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agents approved by the federal food and drug administration.

NY A08075

Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agent approved by the federal food and drug administration.

NY A05432

Relates to administering asthma rescue medications and authorizing schools to possess and administer asthma rescue medications in emergency situations to pupils with a requirement that the parent or guardian of such pupils are notified in writing of such emergency situation.

NY A08383

Authorizes the imposition of bail for certain felony offenses involving the manufacture, sale, distribution, or possession with intent to sell synthetic opioids.

NY S07816

Authorizes the imposition of bail for certain felony offenses involving the manufacture, sale, distribution, or possession with intent to sell synthetic opioids.

NY A10193

Includes all FDA approved forms and doses of Naloxone as opioid antagonists in the state definition of opioid antagonists; requires the department of health to approve all forms and doses of Naloxone approved by the FDA as opioid antagonists.

NY A04945

Requires health insurers to provide coverage for non-opioid treatments utilized for pain management including, but not limited to a drug or biological product that is indicated to produce analgesia without acting upon the body's opioid receptors that has demonstrated the ability to replace, reduce, or avoid opioid use or the quantity of opioids prescribed; or an implantable, reusable, or disposable medical device for the intended use of managing or treating pain that has demonstrated the ability to replace, reduce, or avoid opioid use or the quantity of opioids prescribed.

NY A01499

Relates to presumptions for the death of an injured worker due to opioid overdose where that injured worker was prescribed opioids as a result of his or her workplace injury.

Similar Bills

No similar bills found.